BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wright MJ, Overton HN, Teinor JA, Ding D, Burkhart RA, Cameron JL, He J, Wolfgang CL, Weiss MJ, Javed AA. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. J Gastrointest Surg 2020;24:1590-1596. [DOI: 10.1007/s11605-019-04311-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Nduma BN, Ambe S, Ekhator C, Fonkem E. Geographical Distribution of Pancreatic Cancer in the State of Mississippi by Incidence and Mortality From 2003 to 2019. Cureus 2022. [DOI: 10.7759/cureus.31605] [Reference Citation Analysis]
2 Hao S, Mitsakos A, Popowicz P, Irish W, Snyder RA, Parikh AA. Differential effects of the Affordable Care Act on the stage at presentation and receipt of treatment for pancreatic adenocarcinoma. J Surg Oncol 2022. [PMID: 35699593 DOI: 10.1002/jso.26984] [Reference Citation Analysis]
3 Hamad A, Eskander MF, Shen C, Bhattacharyya O, Fisher JL, Oppong BA, Obeng-Gyasi S, Tsung A. In search of lost time: Delays in adjuvant therapy for pancreatic adenocarcinoma among under-resourced patient populations. Surgery 2022:S0039-6060(22)00248-3. [PMID: 35595567 DOI: 10.1016/j.surg.2022.04.018] [Reference Citation Analysis]
4 Hao S, Mitsakos A, Irish W, Tuttle-Newhall JE, Parikh AA, Snyder RA. Differences in receipt of multimodality therapy by race, insurance status, and socioeconomic disadvantage in patients with resected pancreatic cancer. J Surg Oncol 2022. [PMID: 35315932 DOI: 10.1002/jso.26859] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Fonseca AL, Khan H, Mehari KR, Cherla D, Heslin MJ, Johnston FM. Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review. Ann Surg Oncol. [DOI: 10.1245/s10434-021-11258-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Mitsakos AT, Dennis SO, Parikh AA, Snyder RA. Thirty-day complication rates do not differ by race among patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. J Surg Oncol 2021;123:970-7. [PMID: 33497474 DOI: 10.1002/jso.26383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
7 Hyer JM, Tsilimigras DI, Diaz A, Mirdad RS, Azap RA, Cloyd J, Dillhoff M, Ejaz A, Tsung A, Pawlik TM. High Social Vulnerability and "Textbook Outcomes" after Cancer Operation. J Am Coll Surg 2021;232:351-9. [PMID: 33508426 DOI: 10.1016/j.jamcollsurg.2020.11.024] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 30.0] [Reference Citation Analysis]
8 Kadakia KC, Trufan SJ, Jagosky MH, Worrilow WM, Harrison BW, Broyhill KL, Hwang JJ, Musselwhite LW, Aktas A, Walsh D, Salem ME. Early-onset pancreatic cancer: an institutional series evaluating end-of-life care. Support Care Cancer 2021;29:3613-22. [PMID: 33170401 DOI: 10.1007/s00520-020-05876-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Riner AN, Underwood PW, Yang K, Herremans KM, Cameron ME, Chamala S, Qiu P, George TJ, Permuth JB, Merchant NB, Trevino JG. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. Cancer Med 2020;9:4069-82. [PMID: 32285629 DOI: 10.1002/cam4.3042] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]